title: The inhibitory effect of Shaoyao Ruangan formula on mice with transplanted H22 hepatocarcinoma and its mechanism research.
abstract: BACKGROUND
  The incidence of hepatocellular carcinoma (HCC) is very high in the world. However, a safe and effective strategy is still under research.
  
  
  OBJECTIVE
  Our aim was to demonstrate the inhibitory effect of Shaoyao Ruangan Formmula (SRF) on the tumor of H22-bearing mice and explore its antitumor mechanisms.
  
  
  METHODS
  Corresponding physiological indexes of H22-bearing mice treated with SRF were compared with that of saline treated mice, which could reflect the tumor-suppressing effect of SRF.
  
  
  METHODS
  After treatment, tumor weight, survival time, related gene expression levels etc., were recorded or detected.
  
  
  METHODS
  Data analyzed using a computer SPSS program.
  
  
  CONCLUSIONS
  Comparing with blank control group, the tumor inhibitor rate (IR) of low, middle and high dose group of SRF was 17.72%, 33.99% and 23.73%, respectively. IR of CTX was 43.95%. The results also showed that each group of SRF could prolong the life span of H22-bearing mice to some extent. In addition, reverse transcription polymerase chain reaction (RT-PCR) results revealed that SRF was able to influence related genes expression in the tumor tissues of H22-bearing mice. The expression of TGF-β receptor type II (TBRII) gene was significantly upregulated in each SRF group comparing with normal saline group. On the contrary, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) was significantly downregulated in each SRF group comparing with normal saline group. In summary, SRF showed tumor-suppressing effect on mice with transplanted H22 hepatocarcinoma. The mechanism of antitumor effect may induced by upregulating TBRII expression and down-regulating NF-κB expression.
authors.affiliation: Department of Pharmacy, Zhengjiang Cancer Hospital, Hangzhou, Zhejiang, China.
authors.forename: Hong-yan
authors.initials: HY
authors.lastname: Zhang
authors.forename: Jian-wei
authors.initials: JW
authors.lastname: Jiang
authors.forename: Mao-wei
authors.initials: MW
authors.lastname: Ni
authors.forename: Yun-song
authors.initials: YS
authors.lastname: Peng
authors.forename: Fu-geng
authors.initials: FG
authors.lastname: He
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D016328:NF-kappa B / Q000096:biosynthesis; D017346:Protein Serine-Threonine Kinases / Q000096:biosynthesis*; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000096:biosynthesis*; D023041:Xenograft Model Antitumor Assays
chemical_list: D004365:Drugs, Chinese Herbal; D016328:NF-kappa B; D018125:Receptors, Transforming Growth Factor beta; C000595363:shao yao decoction; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II